Stock Quote & Chart Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Minimum 15 minutes delayed. Source: LSEG
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Innovation is the Best Medicine: How CEO Shane Schaffer and Cingulate Developed “Precision Timed Release,” a New Drug Delivery Platform for ADHD
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301